Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-18 of 18

Sort by

Sort Order Select

Journal Articles

FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML

Blood (2025) 146 (21): 2608–2611.

https://doi.org/10.1182/blood.2025029391

Published: 2025

Includes: Supplemental data

Journal Articles

Determining sensitivity to FLT3 inhibitors prior to therapy in FLT3 mutant acute myelogenous leukemia

Eduardo de Camargo Magalhaes, Salvador Martinez-Bartolome, James Sorrentino, Mahan Abbasian, Antonius Koller, Samanta Catueno, Brandon Brown, Yihua Qiu, Pilgrim Jackson, Steven Kornblau

Blood (2025) 146 (Supplement 1): 3507.

https://doi.org/10.1182/blood-2025-3507

Published: 2025

Journal Articles

Low protein expression of Janus kinase 2 (JAK2) is prognostically adverse and independent of mutation status in acute myelogenous leukemia

Eduardo de Camargo Magalhaes, Samanta Catueno, Brandon Brown, Yihua Qiu, Steven Kornblau

Blood (2025) 146 (Supplement 1): 3494.

https://doi.org/10.1182/blood-2025-3494

Published: 2025

Journal Articles

Changing dogma regarding mutation primacy in acute myelogenous leukemia : Protein expression supersedes mutation status

Steven Kornblau, Eduardo de Camargo Magalhaes, Brandon Brown, Samanta Catueno, Yihua Qiu, Courtney DiNardo, Farhad Ravandi

Blood (2025) 146 (Supplement 1): 3492.

https://doi.org/10.1182/blood-2025-3492

Published: 2025

Journal Articles

Real-world clinical outcomes with novel agent combination therapies for the frontline treatment of pediatric and adult advanced-stage Hodgkin lymphoma

Blood (2025) 146 (Supplement 1): 1852.

https://doi.org/10.1182/blood-2025-1852

Published: 2025

Journal Articles

Positive outcomes associated with stem cell transplantation in pediatric/AYA patients who receive FLAG-IDA-venetoclax for high-risk AML

Irtiza Sheikh, Reeja Raj, Olayinka Okeleji, Samanta Catueno, Aaron Fan, David McCall, Amber Gibson, Miriam Garcia, Jeremy Connors, Michael Roth, Cesar Nunez, Demetrios Petropoulos, Branko Cuglievan, Priti Tewari

Blood (2025) 146 (Supplement 1): 5156.

https://doi.org/10.1182/blood-2025-5156

Published: 2025

Journal Articles

Next-generation sequencing as a powerful tool for measurable residual disease assessment in pediatrics: Identifying time points of true remission

David McCall, Aline Hittle, Branko Cuglievan, Elias Jabbour, Nicholas Short, Nitin Jain, Samanta Catueno, Miriam Garcia, Cesar Nunez, Michael Roth, Laurie Toepfer, Romeo Torres, Amber Gibson

Blood (2025) 146 (Supplement 1): 3370.

https://doi.org/10.1182/blood-2025-3370

Published: 2025

Journal Articles

Low levels of wilms tumor 1 (WT1) protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia

Eduardo de Camargo Magalhaes, Samanta Catueno, Brandon Brown, Yihua Qiu, Steven Kornblau

Blood (2025) 146 (Supplement 1): 5271.

https://doi.org/10.1182/blood-2025-5271

Published: 2025

Journal Articles

Protein levels of isocitrate dehydrogenase 1 and 2 are prognostic and independent of mutation status in acute myelogenous leukemia

Eduardo de Camargo Magalhaes, Samanta Catueno, Brandon Brown, Yihua Qiu, Ian Bouligny, Abhishek Maiti, Courtney DiNardo, Steven Kornblau

Blood (2025) 146 (Supplement 1): 5270.

https://doi.org/10.1182/blood-2025-5270

Published: 2025

Journal Articles

Low levels of enhancer of zeste homolog 2 (EZH2) protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia.

Eduardo de Camargo Magalhaes, Samanta Catueno, Brandon Brown, Yihua Qiu, Mathilde Poplineau, Steven Kornblau

Blood (2025) 146 (Supplement 1): 5259.

https://doi.org/10.1182/blood-2025-5259

Published: 2025

Journal Articles

High protein expression of MDS1 and EVI1 complex locus (MECOM) is prognostically adverse and independent of chromosome 3 rearrangements in acute myelogenous leukemia

Steven Kornblau, Eduardo de Camargo Magalhaes, Samanta Catueno, Brandon Brown, Yihua Qiu, Abhishek Maiti, Tapan Kadia

Blood (2025) 146 (Supplement 1): 5258.

https://doi.org/10.1182/blood-2025-5258

Published: 2025

Journal Articles

Post-transplant maintenance with revumenib in children with HOX-driven AML

Blood (2025) 146 (Supplement 1): 3461.

https://doi.org/10.1182/blood-2025-3461

Published: 2025

Journal Articles

Safety and efficacy analysis of IV iron formulations in children: Results from a large pediatric cohort

Reeja Raj, Samanta Catueno, Kaleigh Riggs-Harpur, Naik Mamta, Karen Williams, Lakshmi Srivaths, Neethu Menon

Blood (2025) 146 (Supplement 1): 2906.

https://doi.org/10.1182/blood-2025-2906

Published: 2025

Journal Articles

Protein expression signatures reveal age-specific risk patterns in B-ALL

Samanta Catueno, Yihua Qiu, Gaye Jenkins, Eduardo de Camargo Magalhaes, Brandon Brown, Rebecca Garris, Branko Cuglievan, Elias Jabbour, Nicholas Short, Terzah Horton, Steven Kornblau

Blood (2025) 146 (Supplement 1): 1593.

https://doi.org/10.1182/blood-2025-1593

Published: 2025

Journal Articles

Cardiac safety of revumenib in children with HOX-driven leukemia: A single-institution cohort

Blood (2025) 146 (Supplement 1): 6950.

https://doi.org/10.1182/blood-2025-6950

Published: 2025

Journal Articles

Cost analysis compared with efficacy shows iron dextran surpassing other intravenous iron formulations in children: A tertiary children's hospital experience

Naik Mamta, Karen Williams, Samanta Catueno, Reeja Raj, Kaleigh Riggs-Harpur, Neethu Menon, Lakshmi Srivaths

Blood (2025) 146 (Supplement 1): 6174.

https://doi.org/10.1182/blood-2025-6174

Published: 2025

Journal Articles

High levels of PTPN11 protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia

Eduardo de Camargo Magalhaes, Samanta Catueno, Brandon Brown, Yihua Qiu, Steven Kornblau

Blood (2025) 146 (Supplement 1): 1700.

https://doi.org/10.1182/blood-2025-1700

Published: 2025

Journal Articles

FLAG IDA Venetoclax in Newly Diagnosed Pediatric and AYA Patients with AML

Reeja Raj, Samanta Catueno, Amber Gibson, David McCall, Miriam B. Garcia, Cesar Nunez, Michael E. Roth, Koji Sasaki, Priti Tewari, Branko Cuglievan, Courtney D. DiNardo

Blood (2024) 144 (Supplement 1): 2906.

https://doi.org/10.1182/blood-2024-211771

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML

Determining sensitivity to FLT3 inhibitors prior to therapy in FLT3 mutant acute myelogenous leukemia

Low protein expression of Janus kinase 2 (JAK2) is prognostically adverse and independent of mutation status in acute myelogenous leukemia

Changing dogma regarding mutation primacy in acute myelogenous leukemia : Protein expression supersedes mutation status

Real-world clinical outcomes with novel agent combination therapies for the frontline treatment of pediatric and adult advanced-stage Hodgkin lymphoma

Positive outcomes associated with stem cell transplantation in pediatric/AYA patients who receive FLAG-IDA-venetoclax for high-risk AML

Next-generation sequencing as a powerful tool for measurable residual disease assessment in pediatrics: Identifying time points of true remission

Low levels of wilms tumor 1 (WT1) protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia

Protein levels of isocitrate dehydrogenase 1 and 2 are prognostic and independent of mutation status in acute myelogenous leukemia

Low levels of enhancer of zeste homolog 2 (EZH2) protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia.

High protein expression of MDS1 and EVI1 complex locus (MECOM) is prognostically adverse and independent of chromosome 3 rearrangements in acute myelogenous leukemia

Post-transplant maintenance with revumenib in children with HOX-driven AML

Safety and efficacy analysis of IV iron formulations in children: Results from a large pediatric cohort

Protein expression signatures reveal age-specific risk patterns in B-ALL

Cardiac safety of revumenib in children with HOX-driven leukemia: A single-institution cohort

Cost analysis compared with efficacy shows iron dextran surpassing other intravenous iron formulations in children: A tertiary children's hospital experience

High levels of PTPN11 protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia

FLAG IDA Venetoclax in Newly Diagnosed Pediatric and AYA Patients with AML

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only